TrialThe oncologist2010

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.

Jacqueline Lehmann-Che et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.